| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.26B | -25.1% |
| Gross profit | ¥0.06B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | -53.8% |
| Gross margin | 24.4% | Net margin 7.4% |
| Revenue Q/Q | -15.9% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.19B | 75.6% |
| R&D | ¥0.02B | 6.2% |
| SG&A | ¥0.02B | 7.1% |
| Tax & other | ¥0.00B | 0.5% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
大族数控 ・ 诚达药业 ・ 朗威股份 ・ 国泰环保 ・ 联特科技 ・ 三元生物 ・ 华兰疫苗 ・ 中亦科技 ・ 联合化学 ・ 金杨精密 ・ 亨迪药业 ・ 联盛化学
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies